Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth (Status and Outlook) 2023-2029

Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth (Status and Outlook) 2023-2029

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
LPI (LP Information)' newest research report, the “Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Forecast” looks at past sales and reviews total world Liposomal and Lipid Nanoparticle Drug Delivery Systems sales in 2022, providing a comprehensive analysis by region and market sector of projected Liposomal and Lipid Nanoparticle Drug Delivery Systems sales for 2023 through 2029. With Liposomal and Lipid Nanoparticle Drug Delivery Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomal and Lipid Nanoparticle Drug Delivery Systems industry.
This Insight Report provides a comprehensive analysis of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomal and Lipid Nanoparticle Drug Delivery Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liposomal and Lipid Nanoparticle Drug Delivery Systems market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomal and Lipid Nanoparticle Drug Delivery Systems and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems.
The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size is projected to grow from US$ 4472.3 million in 2022 to US$ 8924.6 million in 2029; it is expected to grow at a CAGR of 10.4% from 2023 to 2029.
Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal and Lipid Nanoparticle Drug Delivery Systems market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segmentation by application
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences

Please note: The report will take approximately 2 business days to prepare and deliver.